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Abstract. 
ROLE OF MDM2 IN CELL GROWTH REGULATION. 
Rebecca A. Frum, Bachelor of Science, North Carolina State University, Raleigh NC 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006. 
Director: Swati Palit Deb, Ph.D., Associate Professor, Biochemistry 
MDM2 has been shown to induce GO-Gl/S phase arrest. To determine the cell cycle 
step targeted by MDM2, flow cytometry was employed to detect induction of events 
during the GI-S phase transition in MDM2-arrested cells. MDM2 overexpression does 
not prevent expression of cyclin D, cyclin D-CDK mediated phosphorylation of Rb or 
cyclin E in normal, immortal or tumor-derived cells. However, MDM2 down-regulates 
cyclin A expression specifically in normal cells, which is associated with G I  arrest. The 
domain of MDM2 capable of this function is located within its N-terminal 58-109 amino 
acids. To down-regulate cyclin A, MDM2 requires a functional p l61Brg 1 pathway, as 
silencing of either of these proteins disables this function of MDM2. Bromodeoxyuridine 
incorporation studies suggest that another inhibitory domain, ID2, inhibits DNA 
replication, while an MDM2 deletion mutant containing the N-terminal 1-220 amino 
acids including inhibitory domain ID1 does not effectively prevent BrdU incorporation in 
an immortal cell line that is non-responsive to growth arrest by the cyclin A inhibitory 
domain. This suggests that induction of MDM2 leads to GI arrest by at least two 
independent mechanisms, and multiple genetic damages are necessary to overcome 
MDM2-mediated growth arrest. To determine novel interacting partners of MDM2, 
proteomic analysis of MDM2 overexpressed in tumor-derived H1299 cells was carried 
out. This analysis revealed interaction of MDM2 with the translation elongation factor 
efl-a, and was validated by immunoprecipitation and Western blotting and shown to 
colocalize with MDM2 in the cytoplasm. To interact with efl-a, MDM2 was determined 
to require two domains, one of which is located within amino acids 221-325 and another 
within the N-terminal58 amino acids of MDM2. 
H. Chapter 1. Introduction 
MDM2 is potentially oncogenic: The human homologue of the murine double 
minute-2 gene (MDM2) is frequently overexpressed in many human carcinomas, soft 
tissue sarcomas and other cancers (1-17). Amplification of the mdm2 gene enhances 
the tumorigenic potential of murine cells (18,22). Overexpression of mdm2 messenger 
RNA from the amplified gene (5,11,19-20) and enhanced translation of mRNA have 
been proposed as mechanisms of MDM2 overexpression (12,21,23). These findings 
suggest that MDM2 has oncogenic properties. Targeted overexpression of MDM2 in 
transgenic mice causes polyploidy. Overexpression of MDM2 in breast epithelial cells 
inhibits normal development of the mammary gland. (24). Targeted overexpression 
of MDM2 in the basal layer of the epidermis increases papilloma formation by 
chemical carcinogens (25). These findings suggest the requirement of added genetic 
damage for MDM2-induced tumorigenesis. 
MDM2 interacts with the tumor suppressor p53: MDM2 recognizes the 
transactivation domain of p53 and this interaction physically blocks p53-mediated 
transcriptional activation (19,26-31). Work from our laboratory showed that the 
interaction of MDM2 with p53 is needed for inhibition of p53-mediated transactivation 
(27,29). Consistent with its ability to inhibit p53-mediated transactivation, MDM2 
inhibits p53-mediated growth suppression and apoptosis in tumor-derived cells (32-34). 
The p53-regulatory function of MDM2 is required for embryonic development (35,36). 
Wild-type p53 induces MDM2 expression through the P2 promoter by recognizing 
a response element situated downstream of the first exon of the oncogene (37-39). 
Thus, presence of an autoregulatory feedback loop has been suggested, in which a 
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Figure 1. Domains of MDM2. Domains of MDM2 identified for various protein 
interactions and other functions are shown. 
higher level of p53 expression will arrest the cell cycle at the G1 phase and, at the same 
time, will induce MDM2 expression, which in turn will inactivate p53 (40). However, 
recent studies suggest that DNA damaging agents induce phosphorylation of p53 and 
ATM-dependent phosphorylation of MDM2. The phosphorylated p53 and MDM2 are 
incapable of mutual interaction (41-43). 
MDM2 is an E3 ubiquitin ligase and can degrade p53: MDM2 degrades p53 by 
targeting p53 to ubiquitination (44-47). However, mutants of MDM2 lacking the E3 
ubiquitin ligase activity can efficiently bind with wild-type p53 and inhibit p53- 
mediated transcriptional activation (29). This could be a cellular mechanism for 
turnover of p53-MDM2 complexes. This view is also consistent with the fact that 
MDM2 can bind and degrade many other proteins. MDM2 promotes its own 
degradation (48), degradation of mutant p53 (49) and the growth suppressor ~ 1 4 1 ~ 1 9  
ARF (SO). MDM2 binds and degrades the cell-fate protein "numb" (51). Also the 
ubiquitin ligase activity is not required for MDM2-mediated tumorigenesis. 
MDM2 interacts with several growth suppressors and other proteins: MDM2 
interacts with several growth suppressors, including the tumor suppressor p53, the 
retinoblastoma susceptibility gene product Rb and the growth suppressor p14 ARF. 
These interactions are perceived as possible mechanisms for MDM2's oncogenic 
function (reviewed in 52-58; 26-31,59-62). 
MDM2 is induced by oncogenic challenges: Several oncogenic challenges 
induce MDM2 in a p53-dependent or independent manner. Ionizing irradiation, 
including y- and UV-irradiation and DNA damaging agents induce MDM2 expression 
in a p53-dependent manner (33,62-64). UV irradiation also induces p53-nonbinding 
forms of MDM2 (65). DNA-damaging aryl hydrocarbons induce MDM2 expression 
in a p53-independent manner (66). Oncogenic Ras also induces MDM2 through the 
Raf/MEK/MAP kinase pathway in a p53-independent manner (67). These findings 
suggest that normal cells induce MDM2 in response to oncogenic challenges. 
MDM2 induces G1 arrest in non-transformed cells: Considering all the evidence 
for MDM2's oncogenic function, one would expect that overexpression of MDM2 
would confer growth advantage in cultured cells. However, work from our laboratory 
demonstrated that overexpression of MDM2 from its cDNA efficiently arrests the 
growth of NIH3T3 cells (68). MDM2 accomplishes this in NIH3T3 cells by utilizing 
two inhibitory domains, ID1 and ID2, that can independently arrest these cells at the 
GO-Gl/S phase transition (68). Recently, two different laboratories have also reported 
growth inhibitory functions of MDM2 (69,70). Consistent with these observations, 
multiple laboratories have reported that overexpression of MDM2 is a favorable 
prognostic marker in cancer (3,7 1-73). 
The question arises therefore how to reconcile the growth-promoting and growth- 
arresting properties of MDM2. Although overexpression of full-length MDM2 with its 
functional inhibitory domains does not lead to development of antibiotic resistant 
colonies expressing the protein in NIH3T3 cells, injection of nude mice with NIH3T3 
cells stably expressing an MDM2 deletion mutant containing the N-terminal 1-130 
amino acids, thus deleting the inhibitory domains, led to development of tumors at 616 
sites injected. This suggests that MDM2 contains a tumorigenic domain located 
within the N-terminal 1-130 amino acids. Interestingly, this growth-promoting 
domain overlaps with the p53-interacting domain, enforcing the hypothesis that 
MDM2 enhances tumorigenesis by inactivating p53. Since MDM2 can only be stably 
expressed in cells harboring genetic defects such as H1299, this leads to the suggestion 
that MDM2's normal function in the cell is to induce growth arrest, and inactivation of 
the function of its inhibitory domains unleashes its tumorigenic potential. 
Mechanisms of GI-S progression provide a control on cell growth. If MDM2 
arrests cells at the GO-Gl/S phase transition, then cellular defects in one or more of 
these mechanisms in cancer cells may create the cellular context for abrogation of 
MDM2's normal growth suppressing functions and may promote the unmasking of its 
tumorigenic ability. The pathway controlling progression from G1 into S phase 
involves the retinoblastoma susceptibility protein Rb and the activity of cyclin- 
dependent kinases. Cyclins are induced sequentially in the cell division cycle and 
associate with their partner kinases to promote progress through the cell cycle. Cyclin 
D is first induced and associates with CDK416 to phosphorylate Rb at the restriction 
point. Prior to this phosphorylation, the activity of cyclin DlCDK416 is restrained by 
Figure 2. GI-S phase transtion. Components in the Rb pathway to regulate 
progression through GI  into S phase are shown. In panel 1, Rb is shown to bind at the 
cyclin E promoter along with HDAC and Brgl and E2F to repress expression of cyclin E. 
p16 inhibits cyclin D-CDK416 from phosphorylating Rb before the restriction point. In 
panel 2, to enable cells to cross the restriction point thus committing the cell to a round of 
DNA replication, cyclin D-CDK416 phosphorylates Rb, causing HDAC to disassociate 
from Rb and enabling cyclin E to expressed from its promoter. In panel 3, the induced 
cyclin E then associates to its kinase, CDK2, and this complex then further 
phosphorylates Rb and Brgl as well, causing Brgl to leave and leading to induction of 
cyclin A. Induction of cyclin A helps to initiate entry into S phase. 
the cyclin-dependent kinase inhibitor p16, which provides a control to deregulated 
progression through G1. Phosphorylation of Rb by cyclin D/CDK4/6 causes HDAC, 
which was in association with Rb and Brgl to repress the cyclin E promoter, to 
dissociate, leading to expression of cyclin E protein. Cyclin EICDK2 then further 
phosphorylates Rb and Brgl, causing Brgl to leave Rb at the cyclin A promoter, thus 
inducing expression of cyclin A whose activation of CDK2 is required to advance the 
cell into DNA replication in S phase. 
Cancer is the result of multiple genetic defects that lead to loss of control on cell 
growth. Deregulation of GI-S progression and the process of DNA replication may 
provide the cellular context that converts MDM2 from a growth suppressor to an 
oncogene. 
I. Chapter 2. Hypothesis 
a. Major hypothesis. 
The major hypothesis of this work involves deciphering the ways in which the 
human oncoprotein MDM2 regulates cell growth. The objective was to (a) decipher the 
ways in which MDM2 induces cell cycle arrest at the GO-Gl/S phase transition and (b) 
determine novel interactions of MDM2 to further elucidate MDM2's complex cellular 
functions. The hypothesis in (a) was based on the laboratory's previous observation that 
MDM2 induces growth arrest at the GO-Gl/S phase transition in NIH3T3 cells. This is 
accomplished in NIH3T3 through two inhibitory domains of MDM2, ID1 and ID2, which 
are independently capable ot inducing arrest. Since MDM2 can only be stably expressed 
in transformed cells such as H1299, and the function of MDM2 in normal cells is to 
induce GO-Gl/S phase arrest when overexpressed, the hypothesis in (a) was that to 
induce growth arrest MDM2 may be targeting one step in the GO-Gl/S progression, 
while this function is disabled in cells harboring corresponding genetic defects. This 
would suggest an explanation for the ability of some cancer cells to tolerate MDM2 
overexpression. In part (b) the hypothesis was that since MDM2 has been shown to 
interact with numerous proteins, proteomic analysis would reveal novel interacting 
partners of MDM2 which could be validated by other methods. 
b. Specific Aims. 
The following were the specific aims: (1) To determine how MDM2 induces growth 
arrest specifically in normal cells and suggest components of the pathway required for 
this arrest; (2) To determine whether ID1 and ID2 arrest in G1 or inhibit DNA 
replication; (3) To determine novel interacting partners of MDM2 through proteomic 
analysis. 
J. Chapter 3 
MDM2 induces G1 arrest by down-regulating cyclin A through a mechanism 
requiring the pl6lBrgl pathway. 
The manuscript for the work presented in this chapter is currently in preparation. 
a. Introduction. 
Despite MDM2's well-established oncogenic potential, our laboratory has previously 
shown that MDM2 overexpression is capable of inducing GO-Gl/S phase arrest. This is 
accomplished in the immortalized cell line NIH3T3 through two inhibitory domains, ID1 
and ID2. However, although the previous data showed cell cycle arrest using flow 
cytometry, staining DNA to determine cell cycle phase using this method does not allow 
for distinguishing whether the growth arrest is in GO, G1 or initiation into S, as the DNA 
content in these phases should be similar. Therefore, we set out to determine the 
mechanism of MDM2-mediated growth arrest by analyzing MDM2's effect on the 
sequential induction of GI-S proteins as markers for the cell cycle step inhibited by 
MDM2. 
b. Experimental Results. 
Expression of cyclin D, cyclin-D mediated phosphorylated Rb and cyclin E 
is not affected by MDM2. Cyclins are induced in a sequential order as cells progress 
through the cell cycle, and their expression is required to activate cyclin-dependent 
kinases whose activity advances cells through the next step of the cell division cycle. If 
MDM2 arrests the cell cycle at a point after a cyclin is induced, the induction of that 
cyclin and the preceding cell cycle steps should be detected. Failure to detect expression 
of an inducible cell cycle protein at the next step in the process would suggest the point at 
which MDM2 overexpression is arresting cell cycle progression. Since the transfection 
protocols available led to more cells being untransfected than transfected and extract 
made from this population for Western blotting would reflect the average expression of 
the endogenous protein levels of both MDM2 expressing and non-expressing cells, to 
reliably detect the inhibited step we used flow cytometry. This method has the advantage 
of separating transfected from untransfected cells and quantitating the level of the 
endogenous protein being studied in each individual cell. To determine the growth- 
arrested step, we looked for down-regulation of endogenous GI-S cyclins D, E and A as 
well as phosphorylation of Rb at the restriction point by cyclin D-specific kinase in 
response to MDM2 overexpression. We compared normal human lung fibroblast W138 
cells capable of senescence, immortal murine fibroblast NIH3T3 and lung carcinoma 
H1299 cells after transfection with MDM2 to determine any effect of added genetic 
damage on MDM2's ability to arrest the cell cycle. 
Since cyclin D is the first cyclin to be induced as cells enter GI, we first looked for 
any change in level of expression of this cyclin in MDM2 expressing cells compared to 
untransfected cells. MDM2 was detected using a phycoerythrin (PE)-coupled antibody, 
while cyclin D was stained with a flourescein (F1TC)-coupled antibody. Transfected 
MDM2-expressing cells were then separated from untransfected cells in a flow 
cytometer, and a curve was generated to compare cyclin D levels between the two 
populations based on FITC intensity. Figure 3 shows a representative detection of 
transfected cells in W138 cells. Mock-transfected cells were stained with PE-anti-MDM2 
and gated so that background staining in the MDM2-transfected sample using the same 
gate would be represented at 0.1%. This PE staining of the mock sample encompasses 
both endogenous MDM2 levels as well as non-specific staining. The mock cells were 
also stained with a FITC isotype matched to the cyclin D antibody to show non-specific 
binding so that staining of endogenous cyclin D in the transfected sample using the 
specific antibody could be detected over background. Cells in the MDM2-transfected 
sample that stained higher than background on the PE scale were taken as transfected , 
while staining of endogenous cyclin D can be seen as a shift to the right on the FITC 
scale. This method was used for all of the following analyses. 
transfected I 
Figure 3. Detection of transfected cells by flow cytometry. (A) Dot plot of mock- 
transfected W138 cells stained with PE-coupled anti-MDM2 antibody and FITC-coupled 
IgG isotype of cyclin D antibody. The boundary of the mock-transfected cells was drawn 
to achieve 0.1% background staining. (B) Detection of W138 cells successfully 
transfected with MDM2 expression plasmid visualized by flow cytometry. The figure 
shows a dot plot of W138 cells transfected with MDM2 expression plasmid and 
imrnunostained with PE-coupled anti-MDM2 antibody and FITC-coupled cyclin D 
antibody. MDM2-expressing cells are PE-labeled, and are indicated as "transfected. PE- 
unlabeled cells from the same sample are shown as "untransfected". Transfected cells 
overexpressed MDM2 and therefore are more intensely labeled with PE-coupled MDM2 
antibody. 
Comparison of the FITC-cyclin D curves in WI38, NIH3T3 and H1299 cells 
generated in the above manner is shown in Figure 4. The figure plots cell count versus 
FITC-cyclin D intensity, so the peak of each curve represents the maximum level of 
cyclin D in the main cyclin D-expressing population, which should represent a 
synchrony of cells at the same point in GI.  Since transfected cells are shown to have 
stained higher than isotype as seen in the middle panel, this suggests that cyclin D can be 
detected in the transfected cells. Transfected and untransfected cells were taken from the 
same plate and thus were stained in one tube under the same conditions; therefore, any 
decrease in level of cyclin D in the transfected population in comparison to the 
untransfected cells should indicate that MDM2 inhibits the cell cycle at the step of cyclin 
D induction. However, comparison between MDM2-transfected and untransfected cells 
shows that MDM2 does not alter the level of cyclin D in any of the three cell lines tested 
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2 -  untransfe3ed I 2 -tmnsfected = 
8 ai 
l
2 - transfected 
0 
FlTC intensity FlTC intensity FITC intensity 
Figure 4. Cyclin D levels are not altered by MDM2 overexpression. MDM2- 
transfected and untransfected W138 cells were gated and separated after staining with 
a PE-coupled anti-MDM2 antibody, and the comparative FITC intensities of the cyclin 
D-specific antibody transfected or untransfected cells are shown by a single parameter 
histogram. The left panels show comparative FITC intensity of untransfected cells 
stained with FITC-coupled cyclin D antibody and FITC-coupled IgG isotype. As 
expected, the FITC-coupled anti-cyclin D antibody successfully detected cyclin D 
expressing cells and stained cyclin D expressing cells more intensely than the FITC- 
coupled isotype. The middle panels show comparative staining of MDM2 transfected 
cells stained with the cyclin D-coupled FITC antibody compared with cells stained 
with FITC-coupled IgG isotype. In the case of both transfected and untransfected 
cells, which were stained in the same population, cyclin D stained higher with the 
specific antibody than the isotype antibody. The right panels show comparative FITC 
intensity of transfected and untransfected cells stained with FITC-coupled cyclin D 
antibody. In the case of W138 and H1299 cells (and NIH3T3 cells, not shown), there 
was no difference in level of cyclin D between MDM2 and non-MDM2 
overexpressing cells. 
(NIH3T3 not shown), as there is no significant change in the position of the peaks. Since 
cyclin D is expressed as cells enter GI, this suggests that the MDM2-mediated cell cycle 
arrest shown previously by our laboratory (68) is not in GO and that MDM2 arrests the 
cell cycle at a point after cyclin D induction. 
Following cyclin D induction, cyclin D activates its associated kinase CDK416 which 
then phosphorylates Rb at the restriction point. We therefore next checked for any 
change in phosphorylation status of Rb by this specific cyclin/kinase complex using the 
method described above. In Figure 5 ,  comparison of the peak intensity between 
transfected and untransfected cells showed no change in status of cyclin D/kinase- 
mediated phosphorylation of Rb by MDM2 overexpression in any of the three cell lines. 
This suggests that MDM2 enables cells to cross the restriction point before exerting any 
change on the cell cycle. 
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Figure 5. Cyclin D-mediated phosphorylation of Rb levels are not latered by 
MDM2 overexpression. Following the same analysis described for Figure 4, WI38, 
NIH3T3 and H1299 cells were gated for MDM2-expressing and non-expressing cells, 
and intensity of FITC was compared for staining with a FITC-coupled antibody 
specific for cyclin D-mediated phosphorylated Rb. Transfected and untransfected cells 
from the same population both stained more intensely than FITC-coupled isotype 
antibody; however, there was no significant change in level of cyclin D-specific 
phosphorylated Rb between these cells in response to MDM2 overexpression. 
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Figure 6. Cyclin E levels are not altered by MDM2 overexpression. Following 
the same analysis as in Figure 4, WI38, NIH3T3 and HI299 cells were gated to 
separate the MDM2 and non-MDM2 overexpressing populations, and FITC intensity of 
the anti-cyclin E antibody between these cells was compared. Transfected and 
untransfected cells both stained higher for cyclin E-FITC levels than the matched FITC 
isotype antibody; however, there was no significant decrease in level of cyclin E 
mediated by MDM2 overexpression. 
After phosphorylation of Rb at the restriction point, cyclin E is induced: so we next 
looked for any effect of MDM2 on the cell cycle at the level of cyclin E induction. 
However, MDM2 overexpression was found to cause no significant change in cyclin E 
level in either WI38, NIH3T3 or H1299 cells (Figure 6). Therefore, MDM2 affects the 
cell cycle at a point after cyclin E induction. 
MDM2 overexpression down-regulates cyclin A in normal W138 cells. After 
induction of cyclin E, the next cyclin to be expressed in the sequence is cyclin A which 
enables cells to enter S phase, so we analyzed the three cell lines for any reduction in 
cyclin A level mediated by overexpression of MDM2. Using the same method described 
above, we stained MDM2 with a PE-coupled antibody and cyclin A with a FITC-coupled 
antibody. The results in Figure 7 show that MDM2 overexpression in normal W138 cells 
causes a significant (8)-fold reduction in cyclin A levels in comparison to untransfected 
cells, suggesting that MDM2 acts on the cell cycle before S phase begins in these cells. 
Down-regulation of cyclin A level by MDM2 in W138 cells was confirmed by confocal 
nzicroscopy Figure 8. Using this method, we analyzed 50 MDM2-transfected 
W138 cells, and all MDM2-overexpressing cells were found to lack expression of cyclin 
A. By comparison, some untransfected cells in the same field were shown to express 
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Figure 7. Cyclin A levels are down-regulated by MDM2 in W138 cells. MDM2 
overexpressing and non-overexpressing cells were gated after staining with a PE- 
coupled anti-MDM2 antibody. The left panel shows imrnunostaining of untransfected 

expressing MDM2 (FITC-stained) are shown by arrows, and cells expressing cyclin A 
(rhodamine-stained) are shown by block arrows. Nuclei were stained with DAPI. All 
cells expressing MDM2 lacked cyclin A expression. 
Absence of endogenous MDM2 derepresses cyclin A expression. Our data 
suggests that overexpression of MDM2 is capable of down-regulating cyclin A. We 
therefore wanted to determine whether endogenous levels of MDM2 have a role in 
regulating the expression of cyclin A. Since absence of MDM2 has been shown to 
stabilize p53, and p53 can down-regulate cyclin A, instead of knocking down MDM2 
with siRNA we compared endogenous cyclin A levels in normal, p53 knockout, and 
p53IMDM2 double knockout MEFs to show an effect of MDM2 over that of p53. The 
results in Figure 9 show that absence of p53 alone increases cyclin A level approximately 
2-fold over normal MEFs, while knockout of MDM2 along with p53 increases 
endogenous level of cyclin A 5-fold over normal MEFs. This suggests that endogenous 
MDM2 levels contribute to repression of expression of cyclin A. 
- 4- Cyclin A 
-+ Pactin 
Figure 9. Absence of MDM2 derepresses expression of cyclin A. To compare 
level of cyclin A expression in normal, p53-I-, and p53-I-lMDM2-I- MEFs, the cells 
were harvested and the pellet was boiled in equal volume of lammeli loading buffer. 
Equal amounts of the extracts were subjected to SDS-PAGE and cyclin A detected with 
an antibody purchased from Santa Cruz (SC-75 1). 
MDM2 is unable to down-regulate cyclin A in NIH3T3 and HI299 cells. In contrast 
to WI38, the cyclin A level in NIH3T3 or H1299 cells is not altered by overexpression of 
MDM2. Figure 10 shows no significant difference in mean FITC-cyclin A intensity 
between transfected and untransfected cells. Since NIH3T3 cells are immortal and H1299 
are tumor-derived, this suggests that the cellular defects present in these cells allow them 
to overcome this cell-cycle regulatory step mediated by MDM2. 
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Figure 10. Cyclin A levels are unaffected by MDM2 overexpression in 
NIH3T3 and HI299 cells. The figure compares level of FITC intensity of a cyclin A- 
specific antibody in MDM2 transfected and untransfected cells, or each population 
compared with a matched FITC-coupled IgG isotype. The left and middle panels show 
staining of cyclin A expressing cells over nonspecific background binding to FITC- 
coupled IgG isotype of cyclin A antibody in untransfected and transfected cells, 
respectively. The right panels show comparative expression of cyclin A in transfected 
(MDM2-expressing, PE-labeled) and untransfected cells. 
The N-terminal59-109 amino acids of MDM2 down-regulate cyclin A in W138 
cells. The results above demonstrate that full-length MDM2 down-regulates cyclin A in 
normal W138 cells while the same protein is uncapable of this function in NIH3T3 and 
H1299, allowing them to advance past the point of cyclin A induction. Since full-length 
MDM2 was previously shown by our laboratory to inhibit the cell cycle in GO-Gl/S in 
NIH3T3 cells through the ID1 and ID2 domains (68) but our data shows that MDM2 
allows NIH3T3 and H1299 to progress further through G1 than W138 before inducing 
arrest, this suggests that MDM2 contains a third inhibitory domain that is disabled in the 
defective cells. To locate this domain, we separately transfected a series of N- and C- 
terminal deletion mutants of MDM2 into WI38, and stained the fixed cells with both PE- 
MDM2 and FITC-cyclin A antibodies to determine MDM2's effects on cyclin A levels as 
described above. The results in Figure 11 show that a deletion mutant of MDM2, MDM2 
1-109 containing the N-terminal 109 amino acids, is capable of down-regulating cyclin A 
levels in W138 to an extent similar to the wild-type protein. To further define the 
required domain, we used another MDM2 deletion mutant that contains amino acids 59- 
220 and found that on deletion of the N-terminal58 amino acids, MDM2 retains its 
ability to down-regulate cyclin A. This further defines the cyclin A-inhibitory domain 
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Figure 11. The N-terminall-109 amino acids of MDM2 down-regulate 
cyclin A. The left panels shows irnmunostaining of untransfected W138 cells with 
FITC-coupled anti-cyclin A antibody over background staining with FITC-coupled 
IgG isotype of cyclin A antibody. Comparative expression of cyclin A in MDM2 del 
491-1 10 transfected (curve 3) and untransfected (curve 2) W138 cells is also shown. 
to amino acids 59-109 of MDM2. Since our laboratory had previously demonstrated that 
deletion of the N-terminal58 amino acids, which is in the p53-binding domain of 
MDM2, eliminates MDM2's ability to interact with p53 (29), the data in Figure 12 also 
suggests that the MDM2-p53 interaction is not required for MDM2 to down-regulate 
cyclin A. 
The cyclin A inhibitory domain of MDM2 induces G1 arrest in normal W138 
cells but not tumor-derived H1299. Since MDM2 inhibits expression of cyclin A in 
normal but not tumor-derived cells, and induction of cyclin A is required for entry into S 
phase, we hypothesized that transfection of the MDM2 1-109 deletion mutant into W138 
should lead to G1 arrest, while having no effect in H1299. To test this, we transfected 
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Figure 12. Deletion of the N-terminall-58 amino acids of MDM2 does not 
abrogate cyclin A down-regulation by MDM2. The top panel shows the domains of 
MDM2 overlapping with the cyclin A inhibitory domain. The left lower and middle 
panels compare anti-cyclin A-PE staining of untransfected and MDM2 59-220 
transfected W138 cells with a matched PE-coupled isotype, respectively. The lower 
right panel compares cyclin A PE intensity of MDM2 transfected and untransfected 
cells. The boxed middle panel shows further definition of the cyclin A inhibitory 
domain of MDM2 to amino acids 58-109. 
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Figure 13. The N-terminall-109 amino acids of MDM2 induce G1 arrest in 
normal WI38 cells but not tumor-derived HI299 cells. W138 and H1299 cells were 
transfected with MDM2 del491-110 and MDM2 was stained in the fixed cells with an 
FITC-coupled antibody and DNA was stained with either PI or 7AAD. Panel A shows 
mock-transfected W138 cells stained with the MDM2-FITC antibody with a gate drawn 
to achieve 0.1 % background staining. Panel B shows detection of MDM2 del49 1 - 1 10- 
transfected W138 that stain in this gate. Panel C and D show DNA histograms of 
untransfected and MDM2 del491- 1 10 transfected WI38 and H1299 cells, respectively. 
MDM2 1-109 into both W138 and H1299 cells and stained the fixed cells with a FITC- 
MDM2 antibody and DNA with either propidium iodide (PI) or 7-aminoactinomycin D 
(7AAD) to obtain a DNA histogram. A representative gating of MDM2-expressing 
FITC-labeled cells over mock-transfected background in W138 cells is shown in Figure 
13 panels A and B. Generation of a DNA histogram overlay of the transfected and 
untransfected populations showed that MDM2 1-109 led to G1 arrest in W138 but not 
H1299, consistant with the previous finding that MDM2 down-regulates cyclin A in 
normal but not tumor-derived cells, Figure 11 panels C and D. This suggests that the 
domain situated within the N-terminal 1-109 amino acids of MDM2 that is able to down- 
regulate cyclin A is also capable of inducing G1 arrest in normal cells. 
The N-terminall-109 amino acids of MDM2 induce G1 arrest by down- 
regulating cyclin A. If the G1 arrest induced by the MDM2 1-109 domain is a result of 
MDM2 down-regulating cyclin A, forced expression of cyclin A in the presence of the 
MDM2 1-109 expression product should permit cells to bypass the inhibited step. To test 
this, we co-transfected MDM2 1-109 and cyclin A expression plasmids into W138 cells 
in which MDM2 normally down-regulates cyclin A, and compared the DNA histograms 
of the untransfected cells with those positive for both MDM2 and cyclin A expression. In 
this experiment, MDM2 was labeled with a PE-coupled antibody, while cyclin A was 
stained with FITC and DNA was labeled with 7AAD. Figure 14 panel A shows down- 
regulation of cyclin A by 1-109 expression alone, while panel C shows that the level of 
cyclin A in the co-transfected cells is similar to endogenous cyclin A levels in the 
untransfected population. Comparison of the histograms of untransfected and MDM2 1- 
109lcyclin A co-expressing cells in panel D demonstrates that when cyclin A is co- 
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Figure 14. MDM2 induces G1 arrest by down-regulating cyclin A. Comparison 
of cyclin A levels (A, C) and DNA histograms (B, D) of untransfected cells with that of 
MDM2 Del491-110 expression plasrnid transfected (A, B), and MDM2 Del491-110 
and cyclin A expression plasmids cotransfected (C, D) W138 cells. 
expressed with MDM2 1 - 109, the growth inhibition caused by the 1- 109 domain alone 
(panel B) is overcome and cells no longer arrest in G1. This data links the G1 arrest 
function of the MDM2 1-109 domain with this domain's ability to down-regulate cyclin 
A. 
MDM2 requires cyclin-dependent kinase inhibitor p16 to down-regulate cyclin A. 
We wished to investigate the mechanism for down-regulation of cyclin A by MDM2. 
One common cellular defect in cancer is lack of expression of the cyclin-dependent 
kinase inhibitor p16, whose expression is deregulated in greater than 30% of human 
Figure 15. Specific silencing of p16 by siRNA. Silencing of p16 in W138 extracts 
after transfection with 80 pmol of specific siRNA is compared by Western blot with 
equal loading of W138 extracts transfected with 80 pmol of scrambled siRNA. 
cancers. It is known that NIH3T3 cells contain deleted p16 gene, while in H1299 the p16 
gene is methylated, preventing expression of the protein. Since absence of expression of 
p16 is common to both of these cell lines in which MDM2 cannot down-regulate cyclin 
A, and p16 regulates the pathway leading to cyclin A expression, we wanted to determine 
whether MDM2 requires p16 to down-regulate cyclin A. To accomplish this, we turned 
to a p16 siRNA system. Figure 15 shows knockdown of p16 protein expression in W138 
cells by Western blot. We then plated W138 cells onto coverslips after tranfection with 
MDM2 and either scrambled or p16 siRNA, and stained MDM2 and cyclin A for analysis 
by confocal microscopy. Figure 16 shows that transfection of MDM2 with scrambled 
siRNA does not alter MDM2's ability to down-regulate cyclin A. However, when 
MDM2 is co-transfected with p16 siRNA, MDM2 loses its ability to down-regulate 


other genes whose promoters have been methylated as well. Since we have demonstrated 
that silencing of p16 prevents MDM2 from down-regulating cyclin A in W138 cells, and 
MDM2 cannot down-regulate cyclin A in H1299, we hypothesized that treatment of 
H1299 cells with azacytidine should re-enable this function of MDM2 in this cell line. 
To test this hypothesis, we analyzed MDM2's ability to decrease the percent of cyclin A 
expressing cells using flow cytometry or lower luciferase activity from the cyclin A 
promoter in HI299 cells treated with azacytidine compared to buffer treatment alone. 
The results in Figure 18 part A show that azacytidine treatment enables MDM2 
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Figure 18. Treatment of H1299 cells with 5-aza-deoxycytidine partially restores 
the ability of MDM2 to regulate cyclin A expression in HI299 cells. Ability of 
MDM2 Del491-110 (A) to inhibit cyclin A expression, and (B) to inhibit cyclin A 
promoter activity can be reinforced in HI299 cells by re-expressing endogenous p16 after 
5-aza-2'-deoxycytidine treatment. Reinduction of p16 after treatment with 5-aza-2'- 
deoxycytidine is shown by Western. Expression of MDM2 del491-110 is also shown. 
(A) Percent of cyclin A expressing cells in MDM2 Del491-110 expression plasrnid 
transfected and untransfected population after buffer- or 5-aza-2'-deoxycytidine- 
treatment are shown by a bar graph. Cyclin A expression in H1299 cells was determined 
by a FITC-coupled anti-cyclin A antibody, and MDM2 Del49 1 - 1 10 expression was 
detected by a PE-coupled anti-MDM2 antibody. (B) Cyclin A promoter activity was . 
determined by assaying expression of luciferase from a luciferase reporter plasmid under 
the control of cyclin A promoter. For transfection of buffer-treated and 5-aza-2'- 
deoxycyctidine-treated-cells, 200 ng of a cyclin A luciferase reporter plasmid and 2 pg of 
pCMVMDM2 expression plasmids were used. 
Del491-110 to reduce the percent of cyclin A expressing cells to a greater extent than 
azacytidine treatment or MDM2 transfection alone. Similarly in Figure 18 part B, this 
trend was evidenced by decreased luciferase activity from the cyclin A promoter in 
MDM2 transfected cells treated with azacytidine in comparison to azacytidine treatment 
or MDM2 expression alone. These data suggest that treatment of H1299 cells with 
azacytidine partially restores the ability of MDM2 to down-regulate cyclin A. 
MDM2 reduces expression from a cyclin A reporter gene when cotransfected 
with p16 in HI299 cells. Since azacytidine treatment is not specific for demethylation of 
the p16 gene, we wished to confirm that the effects on cyclin A expression by MDM2 in 
the preceding data was due to reinduction of p16 and not global demethylation. 
Therefore, we cotransfected H1299 cells with a cyclin A-luciferase reporter construct and 
MDM2 and p16 plasmids, or with either vector, MDM2 or p16 plasrnids alone, and 
compared the luciferase activity of the extracts. Figure 19 shows that MDM21p16 
cotransfection reduces luciferase activity from the cyclin A promoter approximately 4- 
fold over p16 transfection alone, and 6-fold over MDM2 transfection and 3-fold over 
vector alone. This suggests that re-expression of p16 partially restores MDM2-mediated 
down-regulation of cyclin A in HI299 cells. 
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Figure 19. Cotransfection of p16 with MDM2 enables MDM2 to inhibit 
expression from a cyclin A reporter plasmid. MDM2 inhibits the cyclin A 
promoter after re-expressing p16 in H1299 cells by using a p16 expression plasmid. 
H1299 cells were transfected with 400 ng of a cyclin A luciferase reporter plasmid in 
the presence or absence of 100 ng pCMV p16 or 400 ng pCMV MDM2 expression 
plasmids. Luciferase activity of cell extracts containing equal amounts of proteins was 
determined 24 hours after transfection, shown in the left panel. The right panel shows 
expression of p16 and MDM2 determined by Western blot analysis. Additions of 
expression plasmids during transfection are shown in the figure. Migration of p16, 
MDM2 and P-actin are indicated by arrows. 
MDM2 requires Brgl to down-regulate cyclin A. Another component in the p16- 
dependent pathway to control cyclin A expression is Brgl, part of the chromatin 
remodeling SWVSNF complex, which remains bound to Rb until its phosphorylation by 
cyclin Elcdk2 causes it to leave, thus leading to derepression of cyclin A expression. 
Since phospliorylation of Brgl is accomplished by cyclin Elcdk2, and MDM2 inhibits the 
cell cycle at a point after cyclin E induction, we checked the requirement of Brgl in the 
mechanism for MDM2 to down-regulate cyclin A. After transfectioii of W138 cells with 
MDM2 and either scrambled or Brgl siRNA, we stained MDM2 with a FITC-coupled 
antibody and cyclin A with an antibody coupled to rhodamine and analyzed the cells by 
confocal microscopy. Staining of Brgl in Figure 20 part B shows that Brgl levels were 
down-regulated by the specific siRNA in comparison to scrambled siRNA (Figure 20 
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Figure 20. MDM2 requires Brgl to down-regulate cyclin A. Panel A shows 
detectin of Brgl in the nucleus after transfection with scrambled siRNA, while Panel B 
shows that transfection with Brgl siRNA downregulates this protein in W138 cells. 
Panel C shows the ability of MDM2 to down-regulate cyclin A after transfection with 
scrambled siRNA in WI38 cells (shown by arrows). Panel D shows that after 
transfection of WI38 cells with Brgl siRNA, MDM2 loses its ability to down-regulate 
cyclin A. MDM2 was stained with a FITC-coupled antibody (N20, Santa Cruz), and 
cyclin A was stained with an antibody purchased from Santa Cruz (SC751 TRITC). 
The antibody used to detect Brgl was purchased from Santa Cruz (SC-17796) followed 
by staining with a rhodamine goat anti-mouse secondary antibody from Jackson 
Irnmunoresearch (1 15-295-146). DAPI was used to stain nuclei. 
part A) when visualized using the same settings by confocal microscopy. The data in 
Figure 20 part D demonstrate that in the MDM2/Brgl siRNA transfected cells, MDM2 
loses its ability to down-regulate cyclin A, while MDM2 in the scrambled siRNA 
cotransfected cells retains this function (Figure 20 part C). This data in conjunction with 
the preceding p16 data suggests that MDM2 functions to down-regulate cyclin A 
dependent on the pl6/Brgl pathway. 
c. Chapter Summary. 
To determine one pathway by which MDM2 induces growth arrest, we analyzed 
progression of the cell cycle in MDM2-arrested cells to find the inhibited step by 
detecting the sequential induction of proteins involved in transition from G1 into S phase. 
Flow cytometric analysis in WI38, NIH3T3 and H1299 cells showed no change to cyclin 
D, cyclin D-mediated phosphorylated Rb, or cyclin E levels in response to MDM2 
overexpression, suggesting that the point of inhibition is at a point later than these 
cellular events. However, MDM2 overexpression was found to down-regulate cyclin A 
in normal W138 cells while affecting no change to this cyclin in immortal NIH3T3 or 
tumor-derived H1299 cells. The domain responsible for cyclin A down-regulation is 
located within amino acids 59-109 of MDM2. Absence of endogenous MDM2 
derepresses cyclin A levels in MEFs, suggesting that endogenous MDM2 levels as well 
as MDM2 overexpression assist in down-regulating cyclin A expression. MDM2 induces 
G1 arrest by down-regulating cyclin A, which is expected since cyclin A is required for 
entry into S phase. Silencing of p16 prevents MDM2 from inhibiting cyclin A expression 
in WI38, while reinduction of p16 partially restores this function of MDM2 in H1299 
cells. Down-regulation of cyclin A is also eliminated by absence of Brgl in WI38. 
These data suggest that MDM2 functions to inhibit expression of cyclin A through the 
pl6lBrgl pathway. Since absence of p l 6  expression is a common defect in human 
cancer, this also suggests one mechanistic pathway by which MDM2 is converted from a 
growth inhibitor to a potentially oncogenic protein. 
K. Chapter 4. 
Inhibitory domain 2 (ID2) of MDM2 arrests the cell cycle by inhibiting DNA 
replication. 
The manuscript for the work presented in this chapter is currently in preparation. 
a. Introduction. 
Previous work from our laboratory using flow cytometry showed that MDM2 arrests 
the cell cycle in NIH3T3 cells through two inhibitory domains ID1 and ID2 that function 
in this cell line to arrest the cell cycle at the GOIG1-S phase transition (68). The data 
presented in the preceding chapter demonstrates that a third inhibitory domain located 
between amino acids 59-109 of MDM2 induces G1 arrest by down-regulating cyclin A in 
cells that have a functional pl6lBrgl pathway. Since induction of cyclin A is one of the 
events that initiates entry into S phase but ID1 and ID2 inhibit cell cycle progression at a 
step downstream of cyclin A induction, we hypothesized that these inhibitory domains 
may target cells for arrest at a point prior or later than replication initiation and wanted to 
determine the significance of MDM2 overexpression in the absence of cyclin A down- 
regulation in an immortal or tumor-derived cellular context. 
b. Experimental results. 
A deletion mutant containing the N-terminall-109 amino acids of MDM2 
prevents DNA replication in cells that respond to the cyclin A down-regulatory 
function of this domain. Replication of DNA can be detected using a 
bromodeoxyuridine (BrdU) assay. BrdU is a thymidine analog that is incorporated into 
DNA as replication proceeds. Detection of incorporated BrdU using a flourescently- 
labeled antibody therefore provides a way to determine whether MDM2 overexpfession 
enables cells to enter S phase. To determine the ability of MDM2's inhibitory domains to 
prevent entry into S phase, we transfected normal WI38, immortal NIH3T3, and tumor- 
derived H1299 cells with MDM2 or its deletion mutants. Forty-eight hours after 
transfection, cells were labeled with BrdU to detect replication status and the cells were 
harvested and fixed. MDM2 was stained with a PE-coupled antibody while BrdU was 
labeled with a FITC-coupled antibody, and DNA was stained with 7-AAD. Transfected 
and untransfected cells were gated and analyzed by flow cytometry. The difference 
between the percent of transfected or untransfected cells from the same population that 
incorporated BrdU indicated the ability of the inhibitory domains of MDM2 to inhibit 
DNA replication. The results in Figure 21 show a representative experiment using 
MDM2 del491-110 transfected into W138 cells. The gates were drawn so that 
background staining from the FITC-coupled anti-BrdU antibody in cells that were not 
subjected to BrdU treatment was 0.1% or less. Cells from the untransfected population 
that labeled as BrdU positive on the FITC scale are shown in the M gate in Figure 21 part 
A to be 29.0%, while BrdU negative cells in the L gate are 67.5%. In comparison, only 
7.7% of MDM2 del49 1- 1 10 transfected cells in the M gate in Figure 2 1 part B are 
labeled as BrdU positive, while 91.1 % of the cells in the L gate are BrdU negative. This 
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Figure 21. Detection of BrdU positive cells by flow cytometry. MDM2 del491- 
110 transfected and untransfected cells from the same population were labeled with 
BrdU and were harvested and fixed. Panel A shows detection of cells that were 
actively incorporating BrdU in the untransfected population in the M gate (29%), 
versus cells that did not incorporate BrdU in the L gate (67.5%). MDM2 del491-110 
cells separated from the untransfected population are shown in Panel B to have only 
7.7% of the transfected cells actively incorporating BrdU using the same gate. 
suggests that MDM2 del491-110 prevents entry into S phase in W138 cells as expected 
since this deletion mutant harbors the inhibitory domain that down-regulates cyclin A. 
Similarly, we transfected NIH3T3 and H1299 cells with this deletion mutant and 
analyzed the cells using the same method. The results for all three cell lines are 
summarized in Figure 22. The data shows that in both NIH3T3 and H1299, MDM2 del 
491-1 10 does not have the ability to inhibit DNA replication, as there is no significant 
difference between BrdU incorporation in transfected and untranfected cells. This 
corresponds with the finding in the preceding chapter that the inhibitory domain 
contained within this region of MDM2 down-regulates the S-phase initiating factor cyclin 
A in W138 cells while losing this function in the context of NIH3T3 and H1299 cells. 
Percent BrdU positive cells 
MDM2( - ) MDM2( + ) 
W138 -- 27.1 6.4 
NIH3T3 -- 29.8 34.1 
HI299 -- 35.4 41.9 
Figure 22. Effects of the N-terminall-109 amino acids of MDM2 on BrdU 
incorporation. The cyclin A inhibitory domain inhibits DNA replication only in W138 
cells but not in NIH3T3 or H1299 cells. The chart shows percentage of untransfected 
cells or transfected cells expressing MDM2 or MDM2 Del49 1- 1 10 actively 
incorporating BrdU. Cells expressing MDM2 or MDM2 Del491-110 were detected by 
PE-coupled anti-MDM2 antibody. FITC-coupled anti-BrdU antibody was used to 
detect BrdU incorporating cells. 
The N-terminall-154 amino acids of MDM2 inhibit replication in W138 but not 
NIH3T3 or HI299 cells. We next tested the ability of MDM2 del491-155 to induce a 
block to replication in WI38, NIH3T3 and H1299 cells. Since this deletion mutant 
harbors the cyclin A inhibitory domain but not ID1 or ID2 we expected similar results in 
the three cell lines as was obtained with MDM2 de1491-110. As expected, MDM2 del 
49 1 - 155 was capable of efficiently preventing BrdU incorporation in W138 but not 
NIH3T3 or H1299, as shown in Figure 23. 
Percent BrdU positive cells 
MDM2( - ) MDM2(+ 1 
W138 -- 35.3 10.3 
NIH3T3 -- 30.8 26.6 
HI299 -- 37.2 19.6 
Figure 23. Effects of the N-terminall-154 amino acids of MDM2 on BrdU 
incorporation. The deletion mutant MDM2 del491-155 does not alter the effects on 
BrdU incorporation compared to MDM2 del491-110. BrdU and MDM2 were detected 
as described in Figure 22. 
The N-terminal 1-220 amino acids of MDM2 containing the cyclin A inhibitory 
domain and ID1 inhibit BrdU incorporation efficiently in W138 but not NIH3T3 or 
HI299 cells. Previous data from our laboratory suggested that the growth of NIH3T3 
cells is arrested by MDM2 overexpression through two inhibitory domains that are 
functional in these cells, ID1 and ID2, which can independently arrest the cell cycle at the 
GO-Gl/S phase transition. We therefore wanted to determine whether the deletion 
mutant MDM2 del491-221 containing functional ID1 could inhibit BrdU incorporation 
in NIH3T3 and thus entry into S phase. We transfected this deletion mutant into W138 
and H1299 cells as well to determine its effect in these two cell lines. The results in 
Figure 24 show that this deletion mutant harboring ID1 along with the cyclin A inhibitory 
domain prevents BrdU incorporation in W138 to a similar extent in these cells as the 
MDM2 del491-110 deletion mutant containing the cyclin A inhibitory domain alone. 
However, in NIH3T3 and H1299 cells MDM2 del491-221 does not significantly 
decrease the percent of BrdU positive cells in response to MDM2 overexpression 
compared to untransfected cells, suggesting that this deletion mutant does not inhibit 
initiation to DNA replication in NIH3T3 or H1299. Prior data from the laboratory 
demonstrated that MDM2 del491-221 expression leads to GO-Gl/S arrest in NIH3T3 
through ID1, although inefficiently, while elimination of the N-terminal58 amino acids 
from this deletion mutant increases the efficiency similar to the extent seen with the full- 
length protein in this cell line. To determine whether the N-terminal58 amino acids 
interfere with the ability of ID1 to inhibit BrdU incorporation requires further BrdU 
incorporation experiments using MDM2 59-221. Previous data from the laboratory 
suggests that MDM2 del491-221 cannot be expressed stably in NIH3T3 (68), suggesting 
that inclusive of the contribution from the N-terminal58 amino acids, ID1 is inhibitory to 
the growth of NIH3T3 cells. 
Percent BrdU positive cells 
MDM2( - ) MDM2 ( + 1 
W138 -- 31.1 10.4 
NIH3T3-- 37.1 26.9 
HI299 -- 38.6 20.1 
Figure 24. Effects of the N-terminall-220 amino acids of MDM2 on BrdU 
incorporation. A deletion mutant MDM2 del491-221 including ID1 along with the 
cyclin A inhibitory domain does not significantly inhibit BrdU incorporation in 
NIH3T3 or H1299 cells but maintains an inhibition to BrdU incorporation in W138 
similar to MDM2 del49 1- 1 10 or MDM2 de149 1 - 154. BrdU and MDM2 were detected 
as described in Figure 22. 
Overexpression of full-length MDM2 inhibits BrdU incorporation in WI38, 
NIH3T3 and HI299 cells. We finally tested full-length MDM2 in WI38, NIH3T3 and 
H1299 cells for whether presence of ID2 would lead to an inhibition of replication in 
H1299 or NIH3T3 which incorporate BrdU to the same extent as untransfected cells 
when overexpressing deletion mutants of MDM2 containing ID1 or the cyclin A 
inhibitory domain. The results summarized in Figure 25 show that full-length MDM2 
overexpression in NIH3T3 and H1299 cells inhibits BrdU incorporation as efficiently as 
it does in WI38. Since ID1 and ID2 both arrest the GO-GI-S phase transition by DNA 
histogram in NIH3T3 but ID2 prevents BrdU incorporation in this cell line with 
apparantly minimal effect to this process contibuted by ID1, this suggests that ID2 
functions as the replication inhibitory domain, while ID1 may function after replication 
initiation in the full-length protein, possibly by inhibiting elongation of the DNA strand. 
Further experiments need to be done to confirm this hypothesis. 
Percent BrdU positive cells 
MDM2 ( - ) MDM2(+)  
W138 -- 20.2 7.2 
NIH3T3-- 25.4 9.3 
HI299 -- 36.2 7.0 
Figure 25. Effects of full-length MDM2 on BrdU incorporation. The percent 
of Brdu positive cells is shown in MDM2 overexpressing and non-overexpressing 
WI38, NIH3T3 and HI299 cells. Inclusion of ID2 enables NIH3T3 and H1299 cells to 
prevent BrdU incorporation to a similar extent as W138 cells. BrdU and MDM2 were 
detected as described in Figure 22. 
Accumulation of cellular mutations desensitizes cells to growth arrest mediated 
by MDM2. The preceding data demonstrates that the N-terminal 1-109 amino acids of 
MDM2 prevent BrdU incorporation in normal W138 cells but not immortal NIH3T3 or 
tumor-derived H1299, which is expected since this domain is capable of inhibiting 
expression of cyclin A in W138 but not NIH3T3 or H1299. However the BrdU 
incorporation experiments in this chapter in conjunction with the data in Chapter 3 
suggest that ID2 functions to inhibit DNA replication downsteam of cyclin A induction 
while ID1 apparantly functions downstream of replication initiation. The data presented 
in Chapter 3 shows that cellular defects such as p16, Brgl or p53 deficiency abrogate the 
ability of the N-terminal59- 109 amino acids of MDM2 to downregulate cyclin A and 
lead to G1 arrest, and suggests that further cellular damages may contribute to the 
inactivation of the other inhibitory domains ID1 and ID2. We therefore wanted to assay 
the significance of MDM2 overexpression in the three different cell types to determine 
whether a normal, immortal or tumor-derived cellular context has any consequence for 
the ability of MDM2's inhibitory domains to arrest cell growth. The results in Figure 26 
compare the ability of full-length MDM2 containing the three functional inhibitory 
domains or a deletion mutant MDM2 del 1-120 that contains only ID1 and ID2 to induce 
GI arrest in W138 cells after transfection with 500 ng of either DNA. Both MDM2 and 
MDM2 del 1-120 led to a similar percent increase in the number of cells in GI,  18.9% 
and 15.7%, respectively, from the number of untransfected cells from the same 
population. MDM2 overexpression from 500 ng of plasmid DNA resulted in growth 
arrest with 77.5% of transfected cells in GI, while MDM2 del 1-120 expression from 500 
ng of plasmid DNA led to 81% of transfected cells in GI. This suggests that the cyclin A 
inhibitory domain in full-length MDM2 and ID1 and ID2 present in the MDM2 del 1-120 
deletion mutant can induce growth arrest in normal W138 cells to a similar extent when 
MDM2 is expressed from 500 ng of plasmid DNA, suggesting that dysfunction of the 
pathway utilized by the cyclin A inhibitory domain does not have consequence for the 
ability of MDM2 to induce growth arrest through ID1 and ID2 in the absence of other 
cellular defects at this level of expression. 
Figure 26. Comparison of the ability of full-length MDM2 and a deletion 
mutant of MDM2 harboring ID1 and ID2 to induce G1 arrest in WI38 cells. Full- 
length MDM2 and MDM2 del 1-120 were transfected using 500 ng of either DNA into 
W138 cells. Forty-eight hours after transfection the cells were harvested and fixed. 
MDM2 was stained with 2A10 (courtesy of Arnold Levine) followed by staining with 
an anti-mouse IgG (goat) fluorescein conjugated secondary antibody (Calbiochem 
DC13L). DNA was stained with PI and DNA histograms generated after analysis by 
flow cytometry. Percent increase in GI cells by MDM2 represents the difference in the 
percent of MDM2-expressing cells in GI in comparison to the percent of cells in GI in 
the untransfected population from the same experiment. For the full-length MDM2 
experiment the standard devation for transfected cells in GI was 2.52% while for 
untransfected cells the standard deviation was 0.234%. For the MDM2 del 1-120 
experiment the standard deviation for transfected cells in GI  was 2.0% while for 
untransfected cells it was 0.167%. 
In NIH3T3 and H1299 cells, the cyclin A inhibitory domain is not functional, but 
NIH3T3 is known to induce growth arrest through ID1 and ID2 (68) while we have 
shown in this chapter that H1299 cells do not incorporate BrdU in the presence of ID2 
when full-length MDM2 is expressed from 5 ug of plasrnid DNA. We therefore wanted 
to determine whether the defects present in immortal NIH3T3 would desensitize these 
cells to MDM2-mediated GlIS arrest and whether tumor-derived H1299 cells would be 
further desensitized in the context of their more extensive mutations. To test this, we 
transfected these cells with 500 ng of MDM2 and compared the ability of MDM2 to 
increase the number of G1 cells in the different cell types. Figure 27 shows that MDM2 
expressed from 500 ng of plasmid has a decreasing ability to arrest at GlIS in cells with 
increasing genetic damage. While MDM2 expressed at this level increases the percent of 
GI cells by 18.9% in normal W138 cells, this number is decreased to 15.3% in immortal 
NIH3T3 and is decreased to 6.7% in tumor-derived H1299. To show this difference 
Figure 27. Increasing amounts of cellular mutations lead to desensitivity for 
the growth-arrest function of MDM2 WI38, NIH3T3 and H1299 cells were 
transfected with different concentrations of MDM2 DNA shown in the bar graph. 
Forty-eight hours after transfection the cells were harvested and fixed, and MDM2 was 
stained with 2A10 (provided by Arnold Levine) followed by a anti-mouse IgG (goat) 
fluorescein conjugated secondary antibody (Calbiochem DC13L). DNA was stained 
with PI and DNA histograms were generated by flow cytometry. The percent of cells 
in GI was estimated by using a modfit program. Percent increase in G1 cells by 
MDM2 represents the difference in the percent of MDM2-expressing cells in G1 in 
comparison to the percent of cells in GI in the untransfected population from the same 
experiment. For the 250 ng experiment in W138 the standard devation for transfected 
cells in G1 was 1.74% while for untransfected cells the standard deviation was 0.132%. 
For the 500 ng experiment in W138 the standard devation for transfected cells in G1 
was 2.52% while for untransfected cells the standard deviation was 0.234%. For the 1 pg 
experiment in W138 the standard deviation for transfected cells in G1 was 1.12% while 
for untransfected cells it was 0.232%. For the 250 ng NIH3T3 experiment the standard 
deviation for transfected cells in G1 was 1.23% while for untransfected cells it was 
0.229%. For the 500 ng NIH3T3 experiment the standard deviation for transfected cells 
in G1 was 1.33% while for untransfected cells it was 0.309%. For the 500 ng H1299 
experiment the standard deviation for transfected cells in G1 was 1.23% while for 
untransfected cells it was 0.332%. For the 1 pg H1299 experiment the standard deviation 
for transfected cells in G1 was 2.46% while for untransfected cells it was 0.342% For the 
2 pg H1299 experiment the standard deviation for transfected cells in GI was 1.16% 
while for untransfected cells it was 0.252% 
further between W138 and NIH3T3, we transfected both with 250 ng of MDM2 and 
found that while MDM2 retains the ability to increase the number of G1 cells by 15.4%, 
this is dramatically lowered in NIH3T3 to 8.5%. Even more MDM2 was required to 
achieve efficient GlIS arrest in H1299 similar to WI38, as transfection with 1 pg of 
MDM2 increased the number of G11S cells in H1299 by 20% while a comparable effect 
could be obtained in W138 (18.9%) using only 500 ng of plasmid. Transfection with 2 pg 
of MDM2 increased the efficiency of GIIS arrest in H1299, consistent with this trend. 
These data demonstrate a cell-type variation in response to MDM2 overexpression, 
suggesting that increasing amounts of cellular mutations lead to desensitivity for the 
growth-arrest function of MDM2. 
Chapter summary. 
To determine whether ID1 and ID2 arrest the cell cycle in G1 or S phase, we 
employed BrdU incorporation assays in WI38, NIH3T3 and H1299 cells. Experiments 
using overexpression of the N-terminal 1- 109 amino acids of MDM2 in the three cell 
lines supported the data in Chapter 3 that MDM2 induces G1 arrest by down-regulating 
cyclin A only in normal cells, as this deletion mutant harboring the cyclin A inhibitory 
domain was capable of preventing BrdU incorporation only in W138 cells, and not 
NIH3T3 or H1299. A deletion mutant containing the N-terminal 1-154 amino acids of 
MDM2 did not alter this effect. MDM2 del491-221 containing the cyclin A inhibitory 
domain and ID1 did not significantly decrease the percent of BrdU positive cells in 
NIH3T3 or H1299 cells, suggesting that this deletion mutant does not inhibit initiation to 
DNA replication in NIH3T3 or H1299 cells. However, overexpression of full-length 
MDM2 was capable of inhibiting BrdU incorporation in NIH3T3 and H1299 to a similar 
extent as in W138 cells. This suggests that ID2 is the DNA replication inhibitory domain. 
Flow cytometric analysis of different concentrations of MDM2 transfected into the three 
cell lines showed that MDM2 is capable of inducing G1 arrest at lower levels of 
expression in normal cells, and increasingly higher levels of expression are required for 
similar efficiency in G1 arrest in cells with increasing levels of genetic damage. This 
suggests that added genetic damage leads to toleration of MDM2 overexpression in 
cancer cells. 
L. Chapter 5. 
MDM2 interacting partners: MDM2 interacts with the translation elongation 
factor efl-a. 
The manuscript for the work presented in this chapter is currently in preparation. 
a. Introduction. 
Although MDM2's interaction with the tumor suppressor p53 is considered to be the 
most important, MDM2 interacts with several other proteins involved in cell growth 
regulation. These interactions include tumor suppressors Rb and pl4ARF, as well as 
E2FlIDP1, TATA-binding protein, spl, DNA polymerase epsilon, and SV40 T antigen. 
MDM2 also interacts with its related protein MDMX and ribosomal proteins L5, L11 and 
L23. To determine novel interacting partners of MDM2, we performed proteomic 
analysis of MDM2 overexpressed in the tumor-derived cell line H1299 in an attempt to 
gain more insight into the diversity of MDM2's cellular functions. 
b. Experimental Results. 
Proteomic analysis of MDM2 expressed in HI299 cells. The tumor-derived human 
lung carcinoma cell line H1299 was chosen for proteomic analysis due to its high 
transfection efficiency using the methods available in the laboratory, which would 
facilitate detecting MDM2-associated protein complexes. For this purpose, H1299 cells 
were transfected with either vector or MDM2 plasmids, and the cells were fractionated 
into cytoplasmic and nuclear fractions. After immunoprecipitation with an anti-MDM2 
antibody to pull down MDM2-associated proteins, the beads were eluted and 
subsequently sent for proteomic analysis. The results in Table 1 show the proteins found 
to be in complex with MDM2 in the nuclear and cytoplasmic fractions. This analysis 
confirms MDM2 interactions already identified in the literature, such as ribosomal 
proteins L5, L23 and L l l .  Among the other proteins identified in Table 1, 
56 
Table 1. MDM2 interacting proteins in HI299 cells. 
Nuclear fraction 
ribosomal protein L5 histone H2A 
ribosomal protein L23 histone H2a.z variant isoform 2 
ribosomal protein L 1 1 histone H2B family member A 
ribsomal protein S23 40s histone 3.3B 
elongation factor 1-alpha histone H4 
~ 1 4  protein similar to helix destabilizing protein 
actin gamma cytoskeleton human ATP synthase alpha chain mitochondria1 precursor 
Cytoplasmic fraction 
ribosomal protein L5 beta tubulin 
elongation factor 1-alpha1 actin depolymerizing factor 
ribosomal protein S20 GAPDH 
alpha tubulin ribosomal protein L11 cytosolic 
Table 1. H1299 cells were transfected with MDM2 and prepared for proteomic analysis 
as described in Experimental Designs. The proteins found to interact with MDM2 in 
the cytoplasmic and nuclear fractions are shown in the table. 
we found a novel association of MDM2 in H1299 cells with the translation elongation 
factor efl-a. Efl-a is involved in catalyzing binding of aminoacyl tRNAs to the A site of 
the ribosome during translation and has also been shown to act with the 26s protease 
complex to degrade ubiquitin conjugated proteins, thus providing a possible link between 
protein synthesis and degradation. Since expression of ef l -a  decreases toward the end of 
the life span of mouse and human cells but forced expression of this protein has been 
shown to prolong the lifespan of drosophila and may function to make cells competent 
for growth, we wanted to validate its interaction with MDM2 because of its possible 
implications for MDM2 in regulation of cell growth or other yet-unknown functions. 
MDM2 interacts with efl-a. To confirm MDM2's interaction with efl-a, H1299 
cells were transfected with either vector or MDM2 and the cell lysates were 
immunoprecipitated (IP) using an antibody against efl-a or IgG as a control. Western 
blotting of the proteins bound to the beads showed that the ef l -a  antibody pulled down 
efl-a specifically in comparison to IgG, and MDM2 was detected in the MDM2 
transfected sample and not in the vector or IgG controls (Figure 28). This suggests that 
MDM2 and efl-a specifically interact in H1299 cells, and confirms this interaction from 
our proteomic analysis. 
Pcrnv - - + 
Mdm2 + + - 
Figure 28. Validation of the MDM2-efl-a interaction by Western blot. H1299 
cells were transfected with MDM2 and immunoprecipitated using an anti-efl-a 
antibody (Upstate). MDM2 transfected cells immunoprecipitated using IgG were used 
as a control. Detection of MDM2 and ef l -a  in the Western blot are shown with 
arrows. 
EM-a levels are elevated in cancer cells. It had previously been demonstrated that 
ef l -a  levels are elevated in tumor-derived cells. We therefore compared the endogenous 
level of ef l -a  in normal W138 cells and the tumor-derived cell lines H1299, MCF7 and 
OSACL. Cell extract was made, and equal amounts of the lysate was analyzed by 
Western blotting. The results in Figure 29 show that ef l -a  levels are elevated in the 
tumor-derived cell lines approximately 2-fold in comparison to normal W138 cells, 
correlating with the previously reported data. 
Actin 
Figure 29. EM-a levels are elevated in tumor-derived cells. Extracts were 
made from normal W138 and tumor-derived H1299, MCF7 and OSACL cells and were 
separated by SDS-PAGE. Efl-a and actin expression is shown by arrows. 
MDM2 overexpression does not alter the level of ef l -a  expression. We next 
wanted to determine whether MDM2 overexpression could affect cellular ef 1-a levels, 
and whether this function would be altered in normal versus tumor-derived cells. To 
address this issue, we transfected normal W138 and tumor-derived H1299 cells with 
vector or MDM2 and analyzed the lysates by Western blotting. The results in Figure 30 
show that transfection with MDM2 did not appreciably alter the level of ef l -a  in W138 or 
H1299 cells, suggesting that the function of the interaction is at a level other than 
regulation of expression. 
Figure 30. MDM2 does not affect levels of efl-a protein. W138 and H1299 cells 
were tranfected with either vector pcmv or pcmv MDM2. Forty-eight hours after 
transfection the cells were harvested and lysed, and the extracts separated by SDS- 
PAGE. Expression of MDM2, efl-a and actin are shown by arrows. 
MDM2 and ef l -a  colocalize in the cytoplasm of WI38 cells. Efl-a has been 
shown to be mainly localized in the cytoplasm but has also been detected at lower levels 
in the nucleus. Since MDM2 is mainly a nuclear protein but can also be shuttled into the 
cytoplasm, we wanted to determine where MDM2 and efl-a co-localize in the cell. To 

coupled antibody (Santa Cruz, N20), efl-a was stained with an antibody purchased 
from Upstate, followed by staining with a rhodamine goat anti-mouse secondary 
antibody from Jackson Immunoresearch. Nuclei were stained with DAPI. 
Colocalization of MDM2 and efl-a is visualized as a yellow color. 
Two domains of MDM2 are required for interaction with efl-a. To determine .the 
domains of MDM2 that the protein utilizes to contact efl-a, we employed a series of 
MDM2 deletion mutants by immunoprecipitation to find the required interaction 
domains. To show expression of MDM2 deletion mutants and efl-a, we chose to see the 
interaction from radiolabeled proteins and autoradiography rather than Western blotting 
in which detection of the interacting proteins would be complicated by presence of IgG 
bands. For this purpose, W138 cells were transfected with MDM2 or its deletion mutants. 
Eighteen to twenty-four hours after transfection the cells were labeled with 3 5 ~  
methionine, and the extract from these cells was precleared followed by 
immunoprecipitation with an anti-MDM2 antibody and the gel exposed to film. The 
results in Figure 32 demonstrate that while full-length MDM2 interacts with efl-a 
(shown by an arrow), a deletion mutant MDM2 del491-221 loses its ability to interact, 
suggesting that a domain located between amino acids 221-491 is required for the 
interaction. Following this determination, we tested the ability of MDM2 del491-325 to 
associate with efl-a. Figure 33 shows that similar to the full-length protein, this deletion 
mutant of MDM2 is capable of interaction. This further defines the ef l -a  interaction 
domain to within amino acids 221-325 of MDM2. 
pCMVMDM2del491-221 - - - + 
pCMV MDM2 - - + - 
pCMV + - - -  
Figure 32. MDM2 del491-221 does not interact with efl-a. W138 cells were 
transfected with vector pcmv, pcmv MDM2 or pcmv MDM2 de1491-221. Sixteen to 
24 hours later the cells were translabeled with 3 5 ~  methionine, harvested and equal 
counts were irnmunoprecipitated using an anti-MDM2 antibody-agarose conjugate 
(Santa Cruz, SMP14). Proteins that bound to the beads were washed and subjected to 
polyacrylamide gel electrophoresis, and the dried gel was exposed to film, as described 
in Experimental Designs. The ef l -a  band (identified using extract IPed with an anti- 
ef l -a  antibody) is designated by an arrow. Expression of MDM2 or its deletion mutant 
is shown as the darkest band in their respective lanes. 
pCMV 
Figure 33. MDM2 del491-325 interacts with efl-a. Vector pcmv, pcmv MDM2 
or pcmv MDM2 del491-325 were transfected and identified as described in Figure 33 
and Experimental Designs. The efl-a band (identified using extract IPed with an anti- 
efl-a antibody) is designated by an arrow. Expression of MDM2 or its deletion mutant 
is shown as the darkest band in their respective lanes. 
We next tested an N-terminal deletion mutant MDM2 del 1-58 for its ability to form 
the interaction. The results in Figure 34 show that loss of the N-terminal58 amino acids 
causes MDM2 to lose its ability to associate with efl-a. These data suggest that MDM2 
requires two domains for interaction with efl-a, one which is located between amino 
acids 1-58 and another located between 221-325. Loss of either of these domains is 
enough to prevent MDM2's association with efl-a. 
pCMV MDM2 dell-58 - - - + 
pCMV MDM2 - 
- + -  
PCMV 
Figure 34. MDM2 dell-58 does not interact with efl-a. Vector pcmv, pcmv 
MDM2 or pcmv MDM2 del 1-58 were transfected and identified as described in Figure 
33 and Experimental Designs. The ef l -a  band (identified using extract IPed with an 
anti-efl-a antibody) is designated by an arrow. Expression of MDM2 or its deletion 
mutant is shown as the darkest band in their respective lanes. 
c. Chapter Summary 
To determine novel interactions of the human oncoprotein MDM2, we performed 
proteomic analysis of H1299 cells transfected with MDM2. The results of this analysis 
confirmed some previously reported interactions and showed a novel interaction of 
MDM2 with the translation elongation factor efl-a. To validate this interaction, MDM2 
co-IPed with ef l -a  in HI299 cells, as presence of these two proteins was specifically 
detected in the MDM2-transfected sample by Western blot. Although e f l -a  levels were 
shown to be higher in tumor-derived cells such as H1299 in comparison to normal W138 
cells, MDM2 overexpression was shown to have no effect on expression level of ef l -a  in 
either cell type. MDM2 and efl-a were found to co-localize in the cytoplasm of W138 
cells, supporting the finding that these two proteins interact. Finally, for interaction of 
MDM2 with efl-a, MDM2 was determined to require two domains, one of which is 
located between amino acids 221-325 and another within the first 58 amino acids of 
MDM2. 
M. Discussion. 
Previous data from our laboratory suggested that in spite of its oncogenic potential, 
MDM2 has the ability to induce growth arrest in immortal NIH3T3 cells at the GO-GlIS 
phase transition (68). These cells respond to the growth inhibitory property of MDM2 
through two domains, ID1 and ID2, located on the MDM2 protein within amino acids 
155-220 and 270-324, respectively. A tumorigenic domain found to be located within 
amino acids 1-130 of MDM2 induced tumors in nude mice when injected as stable 
transfectants of NIH3T3 cells. This led to the hypothesis that the normal function of 
MDM2 is to induce growth arrest on overexpression, and inactivation of the growth 
inhibitory domains would turn the overexpressed MDM2 into an active growth- 
promoting protein through the function of its tumorigenic domain. The work in this 
dissertation was centered around deciphering the mechanisms of MDM2-mediated cell 
cycle arrest. Data published previously by our laboratory suggested that MDM2 arrests 
cells at the GO-GlIS phase transition as determined in DNA histograms by flow 
cytometry, but this method does not provide a clear distinction between arrest in GO, GI,  
or early S, since cells in these phases should stain with similar DNA content. Therefore, 
to make this determination we looked for induction of Gl-S cell cycle events in MDM2 
arrested cells as a marker to determine the inhibited step, and compared levels of these 
proteins in the MDM2 overexpressing cells with untransfected cells in the same 
population as controls for normal endogenous levels. Flow cytometry was used in these 
experiments instead of Western, as a method to compare levels of endogenous proteins in 
individual cells in the sorted transfected and untransfected populations. Normal W138 
lung fibroblast, immortal mouse fibroblast NIH3T3 and lung carcinoma H1299 cells were 
used to see the effects of MDM2 in cells with varying degrees of genetic damage. Our 
analyses show that MDM2 does not significantly alter the level of endogenous cyclin D, 
cyclin DICDK specific phosphorylation of Rb or cyclin E in all three cell lines, 
suggesting that MDM2 does not prevent cells from crossing the restriction point. 
However, MDM2 was shown to down-regulate cyclin A specifically in W138 cells. The 
domain of MDM2 involved in this down-regulation was shown to be located within the 
N-terminal59-109 amino acids. Since NIH3T3 cells only respond to arrest by ID1 and 
ID2 and stable transfectants expressing the N-terminal 1-130 amino acids can be 
developed in NIH3T3 cells, this suggests that the cyclin A downregulatory function of 
MDM2 represents a third inhibitory domain whose function is inactivated by the cellular 
defects present in NIH3T3. Consistent with this, our analyses show that in response to 
MDM2 overexpression, NIH3T3 and H1299 cells show no significant decrease in cyclin 
A levels. Since previous data from our laboratory demonstrated that loss of MDM2's N- 
terminal 58 amino acids eliminates its ability to bind p53, the location of the cyclin A 
inhibitory domain between amino acids 59-109 suggests that the MDM2-p53 interaction 
is not required for MDM2 to down-regulate cyclin A. Cyclin A is required for 
progression into S phase, and in agreement with the ability of MDM2 to down-regulate 
cyclin A in normal but not tumor-derived cells, MDM2 del491-110 induced GI arrest in 
W138 but not H1299. The GI arrest function was linked to cyclin A down-regulation by 
the release of GI arrest after cotransfection of W138 cells with MDM2 and cyclin A 
expression plasmids. 
The ability of MDM2 to down-regulate cyclin A in W138 but not NIH3T3 or H1299 
cells suggests that there is a common genetic defect in these cells that prevents MDM2's 
normal function. One common alteration in cancer cells is loss of expression of the 
cyclin-dependent kinase inhibitor p16. In NIH3T3 cells the p16 gene is deleted, while in 
H1299 cells it is methylated, thus preventing its expression. p16 is a component of the Rb 
pathway, and provides an important regulatory control on the GI-S phase transition 
leading to expression of cyclin A (Figure 2). We therefore wanted to determine whether 
MDM2 requires expression of p16 to down-regulate cyclin A. Silencing of p16 in W138 
cells was shown to abrogate the ability of MDM2 to down-regulate cyclin A, visualized 
by confocal microscopy, suggesting it is required for this function of MDM2. Re- 
expression of p16 in H1299 cells either by treatment of cells with 5-aza-deoxycytidine or 
cotransfection with a p16 expression plasmid enabled partial restoration of MDM2's 
ability to decrease the percent of cyclin A expressing cells or inhibit expression from the 
cyclin A promoter, respectively. This suggests the possibility that by restoring function 
of p16 in cancer cells that overexpress MDM2, this could turn potentially oncogenic 
MDM2 into a growth suppressor. Another component of the Rb pathway is Brgl, which 
assembles in complex with Rb at the cyclin A promoter to repress its expression. Using 
Brgl siRNA, confocal imaging shows that although MDM2 can down-regulate cyclin A 
in W138 cells when cotransfected with scrambled siRNA, silencing of Brgl disables this 
process. Thus, another component of the Rb pathway, Brgl, is required for MDM2 to 
down-regulate cyclin A. 
The finding that MDM2 requires the pl6/Brgl pathway to down-regulate cyclin A 
leads to the question of which step in this pathway MDM2 is directly targeting. MDM2 
affects the cell cycle at a point after cyclin E induction and before cyclin A is expressed. 
The known steps in this process that MDM2 could potentially target are the kinase 
activity of cyclin EICDK2 or phosphorylation of Rb or Brgl by this cyclin/kinase 
complex. Experiments done to irnmunoprecipitate cyclin E-associated kinase and 
analyze its ability to phosphorylate histone H1 suggests that MDM2 does not 
significantly affect this kinase activity (data not shown). However, the percent of MDM2 
transfection in these assays was not determined, and since the transfection efficiency may 
be low, an inhibition of cyclin Ekinase activity by MDM2 may be obscured by a high 
percent of contaminating kinase activity from the untransfected cells. Additional 
experiments need to be done to test this hypothesis. An alternative to MDM2 functioning 
by inhibiting cyclin Ekinase activity is the possibility that MDM2 binds to either Rb or 
Brgl, preventing their phosphorylation or preventing Brgl from disassociating from Rb, 
thus enabling repression of the cyclin A promoter. However, preliminary data suggests 
that H1299 cells do not have detectable levels of Brgl. Since MDM2's ability to regulate 
cyclin A expression in H1299 cells can be partially restored by re-expressing p16 in the 
absence of detectable Brgl, while silencing of either p16 or Brgl prevents MDM2 from 
down-regulating cyclin A in W138 cells, this suggests the possibility that MDM2 does not 
directly target either of these proteins but instead requires their contribution toward 
providing the normal cellular framework that prevents deregulation of MDM2's growth 
regulating function. This is supported by MDM2's differential ability to down-regulate 
cyclin A in normal W138 cells, while the unmutated protein loses this function in 
NIH3T3 and H1299 cells which harbor genetic/cellular defects. 
The data presented in Chapter 4 shows that an MDM2 deletion mutant, MDM2 del 
491-1 10 possesses the ability the inhibit BrdU incorporation in W138 but not NIH3T3 or 
H1299 cells. Since this deletion mutant contains the cyclin A inhibitory domain which is 
functional only in the normal cells, the Brdu data supports the function of this domain as 
down-regulating cyclin A, since cyclin A expression initiates progression into S phase 
and subsequent DNA replication. A deletion mutant harboring the N-terminal 1 - 154 
amino acids of MDM2 did not significantly alter the dynamics of BrdU incorporation 
from the effects seen by MDM2 del491-110 in the three cell lines, suggesting that this 
extended domain of MDM2 may not possess DNA replication inhibitory ability. 
Extending the N-terminal portion of MDM2 to include ID1 by transfecting with MDM2 
del491-221 also does not have a significant effect on preventing BrdU incorporation in 
NIH3T3 and H1299 as it does in W138 cells. Although ID1 present in this deletion 
mutant arrests NIH3T3 cells at GO-GUS, though inefficiently, but does not significantly 
prevent BrdU incorporation in these cells, this suggests that ID1 present in this deletion 
mutant may function downstream of initiation of DNA replication. Prior data from the 
laboratory suggested that deletion of the N-terminal58 amino acids from MDM2 del 
491-221 leads to more efficient growth arrest, suggesting that amino acids 1-58 may 
provide a signal that cooperates with the function of ID1. This signal is located within 
the defined tumorigenic domain of MDM2, and if ID1 functions after replication 
initiation it may play a role in this process. Finally, transfection with full-length MDM2 
was found to efficiently inhibit BrdU incorporation in all three cell lines. Since further 
inclusion of ID2 prevents BrdU incorporation by the full-length protein in H1299 and 
NIH3T3 where ID1 and the cyclin A inhibitory domain do not, this suggests that ID2 
prevents replication initiation. Thus, MDM2 possesses three inhibitory domains, each 
functioning potentially at a different step in the cell division cycle. 
In determining the significance of these domains for the cell, a model can be proposed 
in which MDM2 is induced in response to oncogenic challenges in normal cells and 
provides protection against genetic damages by inihibiting cell cycle progession through 
three different mechanisms. Two scenarios can be envisioned. In one, the three 
inhibitory domains of MDM2 provide a way to arrest cells that have already committed 
to replicate and are at different stages of progression after passing the restriction point so 
that once genetic damage is sustained MDM2 has flexibility to inhibit cell growth 
independent of the cell cycle step in which the damage was conferred. In another 
scenario, MDM2 may possess the three inhibitory domains so that it provides multiple 
levels of protection for arresting growth of cells even when cellular defects exist that 
inactivate its function in the other growth inhibitory pathways. The hypothesis that 
multiple genetic damages increasingly desensitize cells to the growth arrest function of 
MDM2 is suggested by the data in Chapter 5 showing that tumor-derived cells which 
harbor more genetic damages require more MDM2 to achieve a growth arrest similar to 
that achieved with the less damaged NIH3T3 and, in turn, MDM2 can arrest normal 
W138 cells with similar efficiency at even lower levels. The hypothesis that MDM2 may 
provide multiple levels of protection is reflected in the multiple mechanisms eukaryotic 
cells use to prevent rereplication of DNA during the normal cell division cycle. For 
example, eukaryotic cells employ cyclin-dependent kinases to phosphorylate the origin 
recognition complex, downregulate cdc6 activity and exclude the MCM2-7 complex 
from the nucleus to prevent re-initiation of DNA replication (74). Evidence presented in 
this dissertation suggests that defects present in the cellular pathways that MDM2 utilizes 
to induce growth arrest may inactivate its function. Ultimately, these damages may not 
only eliminate MDM2's growth suppressive functions but enable MDM2's oncogenic 
function through the action of its tumorigenic domain. 
To find novel protein interactions of MDM2 that may further elucidate MDM2's role 
in cellular processes, we performed proteomic analysis of MDM2 overexpression in 
H1299 cells. This endeavor identified interaction of MDM2 with elongation factor 1- 
alpha (efl-a). The interaction was confirmed by immunoprecipitation and Western 
blotting. MDM2 was found to not significantly alter the expression of ef l -a  in either 
normal W138 or tumor-derived H1299 cells, suggesting that the function or dysfunction 
of the interaction is not to change level of protein expression. Confocal localization 
studies demonstrated that MDM2 and ef l -a  colocalize in the cytoplasm, suggesting this 
is the place for the function of their association. Deletion mutant analysis suggested that 
two domains of MDM2 are required for interaction with efl-a, one located between 
amino acids 1-58 and another between amino acids 221-325. The data presented in 
Chapter 5 identify and validate that MDM2 and ef l -a  interact but leave the question 
open as to the functional significance of the interaction. Ef l - a  is involved in catalyzing 
transfer of aminoacyl tRNAs to the A site during translation, but our prelimary data 
suggests that MDM2 overexpression in H1299 cells does not affect translation. This is 
also evidenced in the fact that our deletion mutant studies to determine the interaction 
domain, which relied on translabeling with "S methionine, led to visualization of labeled 
protein bands in the gel. MDM2 requires two domains to interact with efl-a ,  one 
overlapping with the p53 interaction domain and another with a domain that harbors the 
acidic domain, ID2, and the pl4ARF, spl and Rb binding sites. Since elimination of the 
N-terminal58 amino acids of MDM2 prevents MDM2's interaction with p53 as well as 
interaction with efl-a, this may provide some clue to the function. It is also interesting 
that the other domain required for interaction involves pl4ARF, and association of 
pl4ARF with MDM2 has been shown to stabilize p53. Whether the MDM2-efl-a 
interaction has any role in this process will have to be tested with further experiments. 
N. Experimental Designs. 
General Methods. 
Plasmids and MDM2 deletion mutants. The MDM2 cDNA was a generous gift 
from Bert Vogelstein (23). Construction of plasmids expressing the full-length MDM2 
and its deletion mutants has been described earlier in detail (9, 12). The plasmid 
pCMVpl6 was constructed from a pbluescript p16 plasmid, which was a generous gift 
from Martine Roussel. 
Cells. NIH3T3, WI38, H1299 cells were purchased from American Type Culture 
Collection and were maintained in media suggested by the supplier. NIH3T3 cells were 
maintained in DMEM with 10% calf serum. W138 cells were maintained in Minimum 
Essential Media Eagle with 10% fetal bovine serum. H1299 cells were maintained in 
RPMI with 10% fetal bovine serum. 
Immunofluorescent staining and confocal imaging. Irnmunofluorescent staining 
and confocal imaging were performed following a method reported by Lohrum et a1 (25). 
Briefly, normal diploid W138 cells were seeded on sterile coverslips in a 6-well culture 
dish, and were transfected with 2 pg MDM2 expression plasmid per coverslip. The cells 
were fixed 48 hours after transfection using 4% paraformaldehyde for 10 minutes at room 
temperature with constant shaking. The cells were then washed three times in phosphate 
buffered saline (PBS), permeabilized in ice cold PBS containing 0.2% triton X-100 for 5 
minutes and blocked in PBS containing 0.5% bovine serum albumin at room temperature 
for 30 minutes. For MDM21cyclin A staining, the fixed cells were consecutively 
imrnunostained overnight at 4°C with a FITC-coupled anti-MDM2 antibody (N20, Santa 
Cruz) and a rhodamine-coupled anti-cyclin A antibody (SC75 1 TritC, Santa Cruz) in 
blocking solution. The antibody used to detect Brgl was purchased from Santa Cruz (SC- 
17796) followed by staining with a rhodamine goat anti-mouse secondary antibody from 
Jackson Imrnunoresearch (1 15-295-146). For detection of MDM2lefl-a, cells were 
stained with a FITC-coupled anti-MDM2 antibody (N20, Santa Cruz) followed by 
staining with an anti-efl-a primary antibody (Upstate, 05-235). The secondary antibody 
used against the primary efl-a antibody was a rhodamine goat anti-mouse secondary 
antibody from Jackson Immunoresearch (1 15-295-146). The slides were then washed 
three times in PBS and once in water, air dried and mounted with Prolong Gold Antifade 
with DAPI (Molecular Probes). The coverslips were then analyzed under a confocal 
microscope (Zeiss) under 63X magnification. 
Western blot analysis. Western blot analysis was carried out essentially as 
previously described (12, 17). Briefly, cells were washed three times in PBS and scraped 
from the plate in PBS and transferred to a microfuge tube. Cells were then spun at 900 rcf 
for 10 minutes. The supernatant was removed and cells were lysed in a volume of 
laemmli loading buffer equivalent to the size of the cell pellet and were boiled 5 minutes. 
Cells were separated in a 10% polyacrylamide gel and transferred to 0.45 pm 
nitrocellose. For detecting cyclin A in the blot, cyclin A antibody was purchased from 
Santa Cruz (SC-75 1). p-actin antibody was purchased from Sigma (A-5441). efl-a was 
detected using an antibody from Upstate (05-235). The blots were developed using ECL 
purchased from Amersham. 
Chapter 3 Methods. 
Transfections for flow cytometry. Cells were seeded 18 to 24 hours before 
transfection at 0.4-1 X lo5 cells per 10 cm dish and transfected by the calcium phosphate 
method (9, 12, 17). The cells were transfected with plasmids (10 pg) that express wild 
type or deletion mutants of MDM2. Thirty to forty-eight hours after transfection the cells 
were collected and fixed. In the MDM2Icyclin A cotransfection experiment, W138 cells 
were transfected with 10 pg of a plasmid expressing cyclin A along with 10 pg of a 
plasmid expressing MDM2 del49 1 - 1 10. 
Antibodies. The human cyclin D antibody was reactive for cyclin Dl ,  D2 and D3 
and was used to stain W138 and H1299 cells. For cell cycle analysis in MDM2 Del491- 
110 overexpressing cells a primary antibody to recognize the N-terminal epitope (N20, 
Santa Cruz) and a FITC conjugated secondary anti-rabbit IgG (Oncogene Science) were 
used. FITC conjugated N20 (to detect C-terminal deletion mutant MDM2 Del491-110) 
and FITC conjugated SMP14 (to detect the N-terminal deletion mutants of MDM2) was 
purchased from Santa Cruz. For other flow cytometric experiments N20 was coupled 
with phycoerythrin (PE) using a phycoerythrin conjugation kit (Phycolink) from 
Prozyme. The PE-coupled antibody was separated from unconjugated PE and antibody 
using a Bio-Gel A-0.5m column. D-type cyclins were detected using FITC conjugated 
anti cyclin D antibody set from Pharmingen. The human cyclin D antibody was reactive 
for cyclin Dl,  D2 and D3. The FITC conjugated anti- cyclin E and A antibodies and anti 
Rb antibody for cyclin D- specific phosphorylation site (Ser 795) was purchased from 
Santa Cruz. 
Flow cytometry. Cell cycle Analysis: Methods for cell cycle analysis have been 
described earlier (17, 18, 24). Cells were harvested 30 to 48 hours after transfection and 
fixed with 70% ethanol for overnight at 4°C. The fixed cells were incubated with 
appropriate antibody for 2 hours and an FITC-coupled secondary antibody for one hour 
in PBS, 0.5% BSA and 0.5% Tween 20. Cells were then washed three times in PBS and 
0.5% BSA. To stain DNA with propidium iodide (PI), the cells were incubated with 
0. lmg per ml RNase A, 50 pg per ml propidium iodide, 0.1% NP40 in a trisodium citrate 
buffer for 30 minutes. The samples were analyzed in a fluorescence activated cell sorter 
(Elite, Coulter or FAC  tar^'"" Becton Dickinson) in a flow cytometry core facility. 
Relative levels of MDM2 expression per cell were determined by FITC-fluorescence 
intensity in the green channel (525 nm). Mock-transfected cells were used to determine 
the background fluorescence. Vector-transfected cells or cells transfected with a plasrnid 
expressing an irrelevant protein did not induce growth arrest (17). Cells showing higher 
FITC-fluorescence intensity than mock-transfected cells were gated. The intensity of PI 
staining was recorded in the red channel. 
Comparison of cyclin expression. To estimate and compare levels of cyclins or 
cyclin D-specific Rb phosphorylation, cells were incubated with FITC-coupled 
appropriate antibody or the respective matched IgG isotype after incubation with PE- 
coupled anti-MDM2 antibody. Intensities of the fluorescent dyes were plotted against 
cell number and compared as shown in the Figures. A minimum of 8,000 MDM2 
overexpressing (transfected) cells was analyzed in each experiment. Experiments were 
repeated several times. 
Transfection with p16- or Brgl-siRNA. For confocal experiments with siRNA, 5 
pg of MDM2 expression plasmid was transfected with 80 pmol either p16- or Brgl- 
siRNA using a nucleofector from amaxa. W138 cells were harvested and nucleofected 
using 3 X lo6 cells per transfection and nucleofector Program U-23. After nucleofection, 
cells were plated on sterile coverslips and fixed 48 hours later. 
Transient transfection promoter analysis. Transient transfection promoter analysis 
was performed by a method published by Deb et a1 (26). To determine cyclin A 
promoter activity, H1299 cells were transfected using Fugene 6 (Roche) with a luciferase 
reporter plasmid under the control of luciferase promoter (26) in the presence or absence 
of MDM2 or p16. For this experiment the amount of DNA used was 500 ng of vector, 
100 ng of p16 expression plasmid, and 400 ng of MDM2 expression plasmid. Cell 
extracts containing equal amount of protein were assayed for luciferase activity. 
Luciferase assays were carried out using a commercial kit from Promega. Experiments 
were repeated several times. 
5'-deoxy-azacytidine treatment: H1299 cells were treated for 72 hours with 5-aza- 
2'-deoxycytidine before transfection with MDM2 Del491-110 expression plasmid, and 
the treatment was continued for another 48 hours after which the cells were harvested and 
fixed. 
Chapter 4 Methods. 
Analysis of Bromodeoxyuridine incorporation: Bromodeoxyuridine incorporation 
studies were performed by a method reported earlier (18,24). Cells transfected using the 
calcium phosphate method with hMDM2 expression plasmids or mock-transfected cells 
were incubated with bromodeoxyuridine (BrdU, 10 pM) for 30 to 40 minutes 48 hours 
after transfection. Cells were then harvested by trypsinization, washed and fixed as 
described. Fixed cells were rehydrated and treated consecutively with HCl(2N) and 
sodium borate (O.1M) to partially denature DNA since the antibody can recognize BrdU 
in single-stranded DNA. A PE-coupled hMDM2 antibody and an FITC coupled anti- 
BrdU antibody were used to detect hMDM2 and BrdU respectively. The MDM2-PE 
antibody was described previously in Chapter 3 methods. BrdU was detected using a 
FITC-coupled anti-BrdU monoclonal antibody set from Pharmingen. Cells were then 
incubated with 7AAD (20 pg per ml) to stain DNA and analyzed in a flow cytometry 
core facility. 
Flow cytometry. Different concentrations of MDM2 expression plasmids were 
transfected by nucleofection into WI38, NIH3T3 and H1299 cells. Forty-eight hours 
after transfection the cells were harvested and fixed and stained for flow cytometric 
analysis as described previously using a primary antibody 2AlO (provided by Arnold 
Levine) and an anti-mouse IgG (goat) fluorescein conjugated secondary antibody 
(Calbiochem DC13L). DNA was stained using propidium iodide. 
Chapter 5 Methods. 
Coimmunoprecipitation of MDM2-interacting proteins. To identify MDM2- 
interacting proteins, cells were transfected with an MDM2 expression plasmid using the 
calcium phosphate method (9, 12, 17). Forty-eight hours after transfection, cells were 
washed in DPBS twice and the pellet was suspended in 990 p1 Buffer A (10 mM Hepes, 
10 mM KC1, 1.5 rnM MgC12, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 0.1 mM PMSF, 
and 1X protease inhibitors Calbiochem Cocktail Set I11 (539134)). To this, 10 p1 of 10% 
TritonX-100 was added and the suspension was incubated 5 minutes on ice. Cells were 
spun at 1700g at 4°C for 4 minutes. The supernatant was collected and spun at 20,000g 
at 4°C for 15 minutes for clarification, and the supernatant was taken as the cytoplasmic 
extract. The pellet generated from the Buffer A treatment (nuclei) was suspended in 190 
p1 Buffer A and 1mM CaC12. For every two plates harvested, 1 unit of micrococcal 
nuclease was added. The pellet was vortexed and incubated at 37" for 15 minutes. To 
stop the reaction, 0 . 4 ~ 1  of 250 mM EGTA was added for every two plates harvested. 
Cells were spun at 1700g at 4' for 4 minutes. To lyse the nuclei pellet, 1 ml of 10s 
buffer was added (50 mM Hepes, 0.1M NaC1,0.3% NP40,O.lM Triton-X-100, 10 mM 
NaP04 pH 7.0, 1 mM NaF, 0.14 mM PMSF, 0.5 mM DTT and 1X protease inhibitors 
Calbiochem Cocktail Set I11 (539134)). Lysate was passed through a 2lguage needle, 
lysed on ice 5 minutes and spun at 1700g at 4' for 4 minutes. The supernatant was kept 
as the nuclear extract. Cytoplasmic and nuclear extracts were separately precleared in 
lml of their corresponding buffers using 12 pl normal mouse IgG agarose (Santa Cruz 
SC-2343) for 1.5 hours at 4' with tilting. The beads were pelleted at 800g for 2 minutes 
and MDM2 was immunoprecipitated with a monoclonal antibody coupled directly with 
agarose beads (Santa Cruz, SMP14 SC-965). The immunoprecipitate was washed two 
times to remove contaminating unbound proteins using 10s buffer, followed by two 
washes with 10 mM phosphate pH 6.8. For elution 40 pl of 100 mM glycine pH 2.5 was 
added to the beads and incubated 10 minutes at room temperature. The tubes were spun 
at 100 g for 2 minutes at room temperature and the supernatant was added to 4 1 1  of 0.5M 
phosphate pH 8.0. The elution step was then repeated one additional time. The fractions 
were then desalted using a Microcon filter device (42420) following the manufacturer's 
protocol. Ammonium bicarbonate was then added to a final concentration of O.1M and 
the associated proteins were then digested with trypsin and analyzed by the Peak Parking 
protocol described below. Proteins that bind nonspecifically to either the antibody or IgG 
coupled agarose act as false positives but can usually be identified as such by passing the 
sample through agarose beads coupled to irrelevant antibody. Only proteins that bind 
nonspecifically to the antibody-coupled beads are detected in this experiment and can be 
subtracted from those found in the first experiment. 
Mass spectrometric analysis. Mixtures were analyzed directly in Dr. Hunt's laboratory 
by employing "Peak Parking Technology" developed and patented at the University of 
Virginia (69-70). Immunoprecipitated and eluted samples were digested with trypsin 
and the resulting mixture of tryptic peptides (30 peptideslprotein) were then analyzed by 
nanoflow-HPLC (5-200 nLlmin) interfaced directly to electrospray ionization on a 
ThermoFinnigan, LC-Deca instrument. Peak Parking Technology under control of the 
mass spectrometer data system is employed to extend the sample peak width from 10 sec 
to 200 sec and thus to give the instrument time to record MSMS spectra on more than a 
hundred different peptides that happen to elute in the same 10 sec chromatographic time 
window. Samples were fractionated initially at a flow rate of 200 nLlmin on the 
microcapillary HPLC column and the mass spectrometer was scanned repetitively from 
d z  300-2,000. When sample elutes from the column and the ion current detected by the 
instrument increases above background, the data system reduces flow rate to 4 0  nL1min 
and the instrument repetitively cycles through a program of six scans. (Software for this 
program was developed for Dr. Hunt's laboratory by ThermoFinnigan and is now 
commercially available.) The first spectrum (2 sec) records the masses of (M+H)+ and 
(M+2H)++ ions observed for the components eluting under the chromatographic peak. 
The next five scans (10 sec) record MSMS spectra to generate sequence information on 
the five most abundant species observed in spectrum #l. These masses are then placed 
on an exclusion list along with the corresponding isotope peaks. 
The next scan is used to re-measure ions characteristic of the component molecular 
weights and the next five scans record MSMS spectra on the five most abundant species 
not already on the exclusion list. MSMS spectra can be recorded on as many as 100 
different co-eluting peptides using this protocol. Once the list of candidates to be 
fragmented is exhausted, the flow rate is changed back to 200 nllmin until the next group 
of peptides is detected. The above process is then repeated. At the end of the 
chromatographic run, proteins in the original mixture are identified by processing the 
complete set of MSMS spectra against the protein and nucleic acid databases using the 
SEQUEST software program (71). Up to 6,000 sequences on tryptic peptides can be 
obtained in a single 4 hr chromatographic run with the above technology. Peptides 
present at the 5-10 fmol level in complex mixtures were readily identified with this 
approach. 
Translabeling and immunoprecipation. Cells were transfected with MDM2 
expression plasmids using the nucleofection method. H1299 cells were nucleofected 
using program T-20 while program U-23 was used for W138 cells. In both cases, 3 x106 
cells were used per transfection. Sixteen to 24 hours after transfection, cells were starved 
in methionine-free DMEM for one hour and incubated for two hours in 1.4 ml 
methionine-free DMEM with 10% dialyzed FBS and 16 pl 3 5 ~  methionine. Plates were 
washed three times with PBS and lysed in 10s buffer on ice for 10 minutes. Cells were 
scraped from the plate and passed through a 21 guage needle and spun at 3220 g for 6 
minutes at 4°C. The extracts were precleared for 1.5 hours using normal mouse IgG 
agarose (Santa Cruz SC-2343). Equal counts of each supernatant were 
irnmunoprecipitated with an agarose-conjugated anti-MDM2 antibody (Santa Cruz, 
SMP14 SC-965) overnight at 4' with constant tilting. Beads were then washed three 
times with 10s buffer, one time with 0.8M LiCl followed immediately by one wash with 
TE buffer pH 8.0. After each wash cells were spun at 800 g. The beads were then boiled 
in larnmeli loading buffer and subjected to gel electrophoresis. The gel was incubated for 
1 hour in Enhance (Perkin Elmer 6NE9701) followed by incubation in deionized water 
for exactly 25 minutes and then a 10 minute incubation in 10% acetic acid/2%glycerol. 
The gel was then dried for two hours and exposed to film. 
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